211 related articles for article (PubMed ID: 9144361)
1. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.
Losonsky GA; Lim Y; Motamedi P; Comstock LE; Johnson JA; Morris JG; Tacket CO; Kaper JB; Levine MM
Clin Diagn Lab Immunol; 1997 May; 4(3):264-9. PubMed ID: 9144361
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1.
Qadri F; Mohi G; Hossain J; Azim T; Khan AM; Salam MA; Sack RB; Albert MJ; Svennerholm AM
Clin Diagn Lab Immunol; 1995 Nov; 2(6):685-8. PubMed ID: 8574829
[TBL] [Abstract][Full Text] [Related]
3. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
[TBL] [Abstract][Full Text] [Related]
4. Comparison of O-specific polysaccharide responses in patients following infection with
Kaisar MH; Kelly M; Kamruzzaman M; Bhuiyan TR; Chowdhury F; Khan AI; LaRocque RC; Calderwood SB; Harris JB; Charles RC; Čížová A; Mečárová J; Korcová J; Bystrický S; Kováč P; Xu P; Qadri F; Ryan ET
mSphere; 2023 Oct; 8(5):e0025523. PubMed ID: 37646517
[TBL] [Abstract][Full Text] [Related]
5. Validation and characterization of a human volunteer challenge model for cholera by using frozen bacteria of the new Vibrio cholerae epidemic serotype, O139.
Cohen MB; Giannella RA; Losonsky GA; Lang DR; Parker S; Hawkins JA; Gunther C; Schiff GA
Infect Immun; 1999 Dec; 67(12):6346-9. PubMed ID: 10569748
[TBL] [Abstract][Full Text] [Related]
6. Defining Polysaccharide-Specific Antibody Targets against Vibrio cholerae O139 in Humans following O139 Cholera and following Vaccination with a Commercial Bivalent Oral Cholera Vaccine, and Evaluation of Conjugate Vaccines Targeting O139.
Kamruzzaman M; Kelly M; Charles RC; Harris JB; Calderwood SB; Akter A; Biswas R; Kaisar MH; Bhuiyan TR; Ivers LC; Ternier R; Jerome JG; Pfister HB; Lu X; Soliman SE; Ruttens B; Saksena R; Mečárová J; Čížová A; Qadri F; Bystrický S; Kováč P; Xu P; Ryan ET
mSphere; 2021 Aug; 6(4):e0011421. PubMed ID: 34232076
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.
Qadri F; Wennerås C; Albert MJ; Hossain J; Mannoor K; Begum YA; Mohi G; Salam MA; Sack RB; Svennerholm AM
Infect Immun; 1997 Sep; 65(9):3571-6. PubMed ID: 9284121
[TBL] [Abstract][Full Text] [Related]
8. Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development.
Jonson G; Osek J; Svennerholm AM; Holmgren J
Infect Immun; 1996 Sep; 64(9):3778-85. PubMed ID: 8751929
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera.
Losonsky GA; Yunyongying J; Lim V; Reymann M; Lim YL; Wasserman SS; Levine MM
Infect Immun; 1996 Jan; 64(1):10-5. PubMed ID: 8557325
[TBL] [Abstract][Full Text] [Related]
10. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection.
Losonsky GA; Tacket CO; Wasserman SS; Kaper JB; Levine MM
Infect Immun; 1993 Feb; 61(2):729-33. PubMed ID: 8423098
[TBL] [Abstract][Full Text] [Related]
11. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
12. IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity.
Yang JS; An SJ; Jang MS; Song M; Han SH
PLoS One; 2019; 14(3):e0213507. PubMed ID: 30845262
[TBL] [Abstract][Full Text] [Related]
13. Electrophoretic mobility and immune response of outer membrane proteins of Vibrio cholerae O139.
Pal S; Sasmal D; Guhathakurta B; Nair GB; Bhattacharya SK; Mallick R; Datta A
FEMS Immunol Med Microbiol; 1996 Sep; 15(2-3):143-8. PubMed ID: 8880140
[TBL] [Abstract][Full Text] [Related]
14. Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh.
Qadri F; Svennerholm AM; Shamsuzzaman S; Bhuiyan TR; Harris JB; Ghosh AN; Nair GB; Weintraub A; Faruque SM; Ryan ET; Sack DA; Calderwood SB
Infect Immun; 2005 Oct; 73(10):6577-83. PubMed ID: 16177333
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and protective role of an IgA reactive 31-kDa antigen of Vibrio cholerae O139.
Kumar S; Ray P; Singh H; Ganguly NK
J Med Microbiol; 2001 Jun; 50(6):489-498. PubMed ID: 11393286
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.
Morris JG; Losonsky GE; Johnson JA; Tacket CO; Nataro JP; Panigrahi P; Levin MM
J Infect Dis; 1995 Apr; 171(4):903-8. PubMed ID: 7706818
[TBL] [Abstract][Full Text] [Related]
17. Serum antibacterial and antitoxin responses in clinical cholera caused by Vibrio cholerae O139 Bengal and evaluation of their importance in protection.
Nandy RK; Albert MJ; Ghose AC
Vaccine; 1996 Aug; 14(12):1137-42. PubMed ID: 8911010
[TBL] [Abstract][Full Text] [Related]
18. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.
Kossaczka Z; Shiloach J; Johnson V; Taylor DN; Finkelstein RA; Robbins JB; Szu SC
Infect Immun; 2000 Sep; 68(9):5037-43. PubMed ID: 10948122
[TBL] [Abstract][Full Text] [Related]
19. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh.
Saha D; LaRocque RC; Khan AI; Harris JB; Begum YA; Akramuzzaman SM; Faruque AS; Ryan ET; Qadri F; Calderwood SB
J Infect Dis; 2004 Jun; 189(12):2318-22. PubMed ID: 15181581
[TBL] [Abstract][Full Text] [Related]
20. Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine.
Jertborn M; Svennerholm AM; Holmgren J
Vaccine; 1996 Oct; 14(15):1459-65. PubMed ID: 8994322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
